Refine
Has Fulltext
- yes (8)
Is part of the Bibliography
- yes (8)
Year of publication
- 2018 (8) (remove)
Document Type
- Journal article (5)
- Preprint (3)
Language
- English (8) (remove)
Keywords
- Positronen-Emissions-Tomografie (5)
- PET (4)
- 18F-DCFPyL (3)
- neuroendocrine tumor (3)
- prostate cancer (3)
- theranostics (3)
- PSMA-PET (2)
- Positron Emission Tomography (2)
- Prostate Cancer (2)
- RADS (2)
- Virchow Node (2)
- somatostatin receptor (2)
- AI (1)
- DCGAN (1)
- GAN (1)
- MRI (1)
- Magnetresonanztomografie (1)
- PRRT (1)
- PSMA (1)
- PSMA-RADS (1)
- PSMA-RADS-3A (1)
- PSMA-RADS-3B (1)
- PSMA-targeted PET (1)
- SSTR-PET (1)
- [68Ga]DOTATOC (1)
- artificial intelligence (1)
- interobserver (1)
- interreader (1)
- machine learning (1)
- magnetic resonance imaging (1)
- peptide receptor radionuclide therapy (1)
- personalized medicine (1)
- positron emission tomography (1)
- prostate-specific membrane antigen (1)
- prostate-specific membrane antigen (PSMA) (1)
- quantification (1)
- reporting and data system (1)
- reporting and data systems (1)
- somatostatin receptor (SSTR) (1)
- standardization (1)
- stroke (1)
Institute
- Klinik und Poliklinik für Nuklearmedizin (8) (remove)
Sonstige beteiligte Institutionen
EU-Project number / Contract (GA) number
- 701983 (8)
Purpose: Prostate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET) imaging has become commonly utilized in patients with prostate cancer (PCa). The PSMA reporting and data system version 1.0 (PSMA-RADS version 1.0) categorizes lesions on the basis of the likelihood of PCa involvement, with PSMA-RADS-3A (soft tissue) and PSMA-RADS-3B (bone) lesions being indeterminate for the presence of disease. We retrospectively reviewed the imaging follow-up of such lesions to determine the rate at which they underwent changes suggestive of underlying PCa.
Methods: PET/CT imaging with \(^{18}\)F-DCFPyL was carried out in 110 patients with PCa and lesions were categorized according to PSMA-RADS Version 1.0. 56/110 (50.9%) patients were determined to have indeterminate PSMA-RADS-3A or PSMA-RADS-3B lesions and 22/56 (39.3%) patients had adequate follow-up to be included in the analysis. The maximum standardized uptake values (SUV\(_{max}\)) of the lesions were obtained and the ratios of SUV\(_{max}\) of the lesions to SUV\(_{mean}\) of blood pool (SUV\(_{max}\)-lesion/SUV\(_{mean}\)-bloodpool) were calculated. Pre-determined criteria were used to evaluate the PSMA-RADS-3A and PSMA-RADS-3B lesions on follow-up imaging to determine if they demonstrated evidence of underlying malignancy.
Results: A total of 46 lesions in 22 patients were considered indeterminate for PCa (i.e. PSMA-RADS-3A (32 lesions) or PSMA-RADS-3B (14 lesions)) and were evaluable on follow-up imaging. 27/46 (58.7%) lesions demonstrated changes on follow-up imaging consistent with the presence of underlying PCa at baseline. These lesions included 24/32 (75.0%) PSMA-RADS-3A lesions and 3/14 (21.4%) lesions categorized as PSMA-RADS-3B. The ranges of SUVmax and SUVmax-lesion/SUVmean-bloodpool overlapped between those lesions demonstrating changes consistent with malignancy on follow-up imaging and those lesions that remained unchanged on follow-up.
Conclusion: PSMA-RADS-3A and PSMA-RADS-3B lesions are truly indeterminate in that proportions of findings in both categories demonstrate evidence of malignancy on follow-up imaging. Overall, PSMA-RADS-3A lesions are more likely than PSMA-RADS-3B lesions to represent sites of PCa and this information should be taken into when guiding patient therapy.